Description: Avivagen Inc. is a life sciences company. The Company is developing and commercializing products to replace antibiotics in livestock feeds for growth promotion and to help prevent disease by supporting the animal's own health defenses. It operates through two segments: products based on fully-oxidized beta-carotene (OxC-beta) technology and chemistry product sales. Its OxC-beta technology is in trials as a non-antibiotic feed additive. Its products include OxC-beta Livestock, Vivamune Vital Health3 Chews and Oximunol Chewable Tablets. Its Vivamune Vital Health3 Chews are natural supplements that are suitable for pets in all life stages and can be given to dogs and cats as young as six weeks of age. The Oximunol Chewable Tablets are available in bottles of 50, through veterinarians across the United States. It develops science-based, natural health products for animals that are proven in clinical trials. The OxC-beta Livestock is available for sale in Thailand and the Philippines.
Home Page: www.avivagen.com
VIV Technical Analysis
100 Sussex Drive
Ottawa,
ON
K1A 0R6
Canada
Phone:
613 702 2908
Officers
| Name | Title |
|---|---|
| Mr. G. F. Kym Anthony | CEO & Director |
| Dr. Graham Burton Ph.D. | Co-Founder, Chief Scientific Officer & Director |
| Dr. James Nickerson Ph.D. | Pres and Exec. VP of Bus. Devel. & Product Innovation |
| Mr. Ira Levy | Interim Chief Financial Officer |
| Mr. Drew Basek | Director of Investor Relations |
| Ms. Tracy Gillett BVSC | Director of Companion Animal & Marketing Mang. |
Exchange: V
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 17.2046 |
| IPO Date: | |
| Fiscal Year End: | October |
| Full Time Employees: | 13 |